PubMed · 8650763
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
K P Andersen. 1996-03-25. [Questionable fish oils?].. https://pubmed.ncbi.nlm.nih.gov/8650763/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
OBJECTIVE: To investigate the changes in plasma lipids and lipoproteins, low-density lipoprotein (LDL) oxidizability, and plasma homocysteine during postmenopausal sequential 3-monthly hormone replacement therapy. DESIGN: Open longitudinal prospective study. SETTING: Gynecological outpatient department of a university hospital. PATIENT(S): Thirty-nine healthy nonhysterectomized postmenopausal women. INTERVENTION(S): Oral conjugated estrogen, 0.625 mg/d, combined with oral medrogestone 10 mg/d during the last 14 days of each 84-day treatment cycle. The treatment was given for four treatment cycles of 84 days (1 year). MAIN OUTCOME MEASURE(S): Plasma lipids and lipoproteins, LDL oxidizability, and plasma homocysteine. RESULT(S): After 1 year of treatment plasma concentrations of total cholesterol and LDL cholesterol were 3.5% and 8.7% lower, respectively. High density lipoprotein cholesterol, apolipoprotein A-I, and triglycerides were 6.5%, 9.0% and 16% higher, respectively. Apolipoprotein B concentration remained unchanged. The results on LDL oxidizability were inconsistent. Plasma homocysteine decreased with 12.3% during the first 6 months of treatment in women with higher homocysteine concentrations at baseline. These values returned to baseline levels during the second half year of treatment. CONCLUSION(S): This sequential hormone regimen induced beneficial changes in the conventional lipid and lipoprotein risk estimators, whereas the observed changes in the other markers remained inconclusive and/or of minor importance.
Explore the source record for details and available documents.